Experimental combo therapy aims to outsmart leukemia without dangerous side effects
NCT ID NCT05507827
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests whether giving specially engineered donor immune cells (CAR T cells) along with a special stem cell transplant (Orca-T) is safe for adults with a high-risk type of leukemia called B-cell ALL. The approach is designed to help the donor cells attack the leukemia while reducing the chance of the donor cells attacking the patient's body. The study involves 22 participants and focuses on safety and engraftment success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Donor-derived CD19/CD22-CAR T cells and Orca-T (regulatory T cells plus stem cells)
What this could lead to
If it works, this could offer a new way to treat B-cell ALL by boosting the immune system's ability to fight leukemia while reducing the risk of graft-versus-host disease.
What could go wrong
This is a very early (Phase 1) and small trial (22 people), so safety and effectiveness are not yet proven. There are risks of severe side effects from the chemotherapy, graft failure, or serious immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford Cancer Center
Palo Alto, California, 94305, United States